Budget Impact analysis of a new system of care in Parkinson’s disease patients
Open Access
- 19 September 2022
- journal article
- research article
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 9, 91-98
- https://doi.org/10.33393/grhta.2022.2413
Abstract
Objective: To estimate the economic impact of the introduction of a new care system based on apomorphine and Patient Support Program for motor fluctuations (“on-off” phenomena) in patients with Parkinson’s disease which are not sufficiently controlled by oral anti-Parkinson medication in Italy. Method: A Budget Impact model was developed to evaluate the new care system in patients with Parkinson’s disease over a 3-years’ time horizon. The comparator treatments included in the analysis were treatments based on apomorphine and levodopa + carbidopa. The analysis was conducted from a National Health Service (NHS) perspective. Costs included in the analysis were acquisition costs and device costs. A deterministic sensitivity analysis was carried out to evaluate the uncertainty of the parameters used. A break-even analysis was conducted to identify the minimum number of subjects that would need to be treated with the new care system to obtain a positive Budget Impact (World With – World Without = 0). Results: The analysis shows that the introduction of the new care system based on apomorphine could generate a cost saving incurred by the NHS of over € 5.7 million in 3 years. Break-even analysis shows that if it were possible to intercept with the new treatment at least 9 patients treated with apomorphine, there would not be an increase in costs for the NHS. Conclusion: The new care system would respond to the unmet needs of patients with Parkinson’s disease by generating a reduction in the expenditure incurred by NHS.Keywords
This publication has 12 references indexed in Scilit:
- Current and projected future economic burden of Parkinson’s disease in the U.S.npj Parkinson's Disease, 2020
- Are All Dopamine Agonists Essentially the Same?Drugs, 2019
- Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trialThe Lancet Neurology, 2018
- Apomorphine - pharmacological properties and clinical trials in Parkinson's diseaseParkinsonism & Related Disorders, 2016
- Apomorphine and levodopa in Parkinson's disease: Two revolutionary drugs from the 1950'sParkinsonism & Related Disorders, 2016
- Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trialThe Lancet Neurology, 2015
- Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task ForceValue in Health, 2014
- Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy studyThe Lancet Neurology, 2013
- Costs of illness and care in Parkinson's Disease: An evaluation in six countriesEuropean Neuropsychopharmacology, 2011
- Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact AnalysisValue in Health, 2007